SUBSCRIBERS
AstraZeneca shares plunge as the firm's lung cancer study fails
Published Thu, Jul 27, 2017 · 09:50 PM
London
ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.
The so-called Mystic study was the most anticipated clinical experiment in the pharmaceutical industry this year and the news saw the shares tumble more than 15 per cent in early trade, putting them on track for their worst day ever.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices